ArticleCancer immunology, immunotherapy : CII2026
Decorin facilitates T cell-mediated antitumor immunity and augments the efficacy of anti-PD1 immunotherapy.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDecorin (DCN) predominantly produced by fibroblasts is a small leucine-rich proteoglycan with tumor-suppressive property. However, whether DCN has a role in shaping the tumor immune microenvironment remains elusive.
methodsThe TCGA and GEO databases were analyzed to identify fibroblast-specific secretory proteins that are downregulated in most types of human tumors, positively correlate with CD8⁺ T cell infiltration, and associate with improved response to immune checkpoint blockade (ICB) therapy. The function of DCN in vivo was assessed using cell lines with stable DCN overexpression in both immunocompetent and immunodeficient mice. The changes in the composition and function of immune cell subpopulations in tumors were analyzed by flow cytometry analysis (FCM) and immunofluorescence staining. The role of CD8⁺ T cells in the DCN-mediated tumor suppression was further elucidated by utilizing B2m-knockout tumor cells and CD8⁺ T cell depletion assays. The in vitro co-culture system of tumor cells and T cells was applied to dissect the effects of DCN on CD8
resultsDCN-mediated tumor suppression was present in immunocompetent mice, wherein either depletion of CD8⁺ T cells in mice or ablation of β2M in tumor cells abrogated the tumor-inhibitory effects mediated by DCN, indicating the importance of CD8⁺ T cells in the DCN-antitumor activities. DCN overexpression promoted CD8⁺ T cell infiltration into tumors and increased the production of TNF-α, IFN-γ, and perforin in infiltrating T cells, and DCN expression substantially enhanced the tumor-suppressive efficacy of anti-PD1 therapy. More importantly, integrative analyses of clinical data indicated that DCN expression is downregulated in multiple types of human tumors and positively associated with the presence of CD8⁺ T cells and their expression of cytotoxic genes. Furthermore, high DCN levels were correlated with favorable prognosis in certain types of cancer patients with ICB therapy.
conclusionsOur study reveals that DCN functions as a tumor-suppressive factor by enhancing T cell response, and proposes the potential of exogenous DCN as a supplement to cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.